Clinical trial
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled…
NCT03347279 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT03347279 |
|---|---|
| Title | Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma |
| Official title | A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR) |
| Acronym | NAVIGATOR |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Biological, Other |
| Interventions | Experimental: Tezepelumab, Placebo |
| Enrollment | 1,061 |
| Start date | Nov 23, 2017 |
| Primary completion | Sep 8, 2020 |
| Completion | Nov 12, 2020 |
| First posted | Nov 20, 2017 |
| Last update posted | Nov 26, 2021 |
| Countries | Argentina, Australia, Austria, Brazil, Canada, France, Germany, Israel, Japan, Russia, Saudi Arabia, South Africa and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: